2-氯嘧啶-5-羧酸 、 三乙胺 、 4-氨基四氢吡喃 以
1,4-二氧六环 为溶剂,
反应 0.5h,
以to give the title compound (701 mg, crude) as a beige solid的产率得到2-[(Oxan-4-yl)amino]pyrimidine-5-carboxylic Acid
[EN] IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS<br/>[FR] DÉRIVÉS D'IMIDAZO[4,5-C]PYRIDINE ET DE PYRROLO[2,3-C]PYRIDINE EN TANT QU'INHIBITEURS SSAO
申请人:PROXIMAGEN LTD
公开号:WO2014140592A1
公开(公告)日:2014-09-18
The compounds of formula (I) are inhibitors of semicarbazide- sensitive amine oxidase (SSAO) activity useful in the treatment of inflammation, an inflammatory disease, an immune or an autoimmune disorder, or inhibition of tumour growth.
The present invention provides certain compounds according to formula (I) which are inhibitors of SSAO activity
wherein V, W, X, Y, Z, R
1
and R
2
are as defined in the specification.
[EN] IMIDAZO[4,5-C]PYRIDINE DERIVED SSAO INHIBITORS<br/>[FR] INHIBITEUR DE SSAO DÉRIVÉ D'IMIDAZO[4,5-C]PYRIDINE
申请人:PROXIMAGEN LTD
公开号:WO2016042331A1
公开(公告)日:2016-03-24
A compound as set out in claim 1, and the use of the same in therapy.
权利要求1中所述的化合物,以及将其用于治疗。
IMIDAZO[4,5-C]PYRIDINE AND PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS SSAO INHIBITORS
申请人:PROXIMAGEN LIMITED
公开号:US20160046622A1
公开(公告)日:2016-02-18
The compounds of formula (I) are inhibitors of semicarbazide-sensitive amine oxidase (SSAO) activity useful in the treatment of inflammation, an inflammatory disease, an immune or an autoimmune disorder, or inhibition of tumour growth.
Substituted imidazo[4,5-c]pyridines as SSAO inhibitors
申请人:Proximagen Limited
公开号:US10065954B2
公开(公告)日:2018-09-04
Specific compounds of formula (Ia):
and pharmaceutically acceptable salts thereof. Pharmaceutical compositions of the specific compounds of formula (Ia) and pharmaceutically acceptable salts thereof. A method for inhibiting tumor growth in a subject that includes administering to the subject an effective amount of a compound selected from the specific compounds of formula (Ia) and pharmaceutically acceptable salts thereof. A method for modulating semicarbazide-sensitive amine oxidase activity in a subject that includes administering to the subject an effective amount of a compound selected from the specific compounds of formula (Ia) and pharmaceutically acceptable salts thereof.